GSK plc (NYSE:GSK) on Monday reported interim results from its registrational Phase 2 AZUR-1 trial of Jemperli (dostarlimab) in rectal cancer patients.
The data showed that its immunotherapy Jemperli achieved a meaningful and sustained clinical complete response at 12 months in patients with stage II/III mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) locally advanced rectal cancer.
The company said the findings could position the drug, if approved, as the first immunotherapy capable of eliminating or delaying the need for chemotherapy, radiation, and surgery for some patients.
AZUR-1 Trial Meets Primary Objective The single-arm AZUR-1 study met its primary endpoint by demonstrating a sustained clinical complete response at 12 months.
The trial enrolled 154 patients, each receiving nine cycles of dostarlimab over six months.
